SCHEMBL4824243

SCHEMBL4824243

Cc1ccc([N+](=O)[O-])cc1NC(=O)c1cc(Cl)ccc1[N+](=O)[O-]

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.60
ALDH1A1 P00352 4/20 0.60
TNF P01375 1/20 0.59
NOD1 Q9Y239 1/20 0.59
HTT P42858 4/20 0.58
SMN1; SMN2 Q16637 3/20 0.58
MAPT P10636 3/20 0.58
MEN1 O00255 4/20 0.57
NPC1 O15118 2/20 0.57
LMNA P02545 2/20 0.57
RAB9A P51151 2/20 0.57
AURKA O14965 1/20 0.57
PDPK1 O15530 1/20 0.57
JAK2 O60674 1/20 0.57
GMNN O75496 1/20 0.57
EGFR P00533 1/20 0.57
TP53 P04637 1/20 0.57
CYP1A2 P05177 1/20 0.57
LYN P07948 1/20 0.57
CHRM2 P08172 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12010997 0.88 KMT2A (0.74) KMT2AALDH1A1TNFNOD1HTT
SCHEMBL10743441 0.84 RORC (0.61) KMT2AALDH1A1TNFNOD1HTT
SCHEMBL11724420 0.83 KMT2A (0.55) KMT2AALDH1A1TNFNOD1HTT
SCHEMBL5803852 0.80 ALDH1A1 (0.68) ALDH1A1MAPTLMNAKCNMA1
SCHEMBL4824126 0.78 SIRT6 (0.65) KMT2AALDH1A1MAPTMEN1CYP2D6
SCHEMBL18341379 0.78 KMT2A (0.78) KMT2AALDH1A1HTTSMN1; SMN2MAPT
SCHEMBL2690154 0.78 RORC (0.64) KMT2AALDH1A1HTTSMN1; SMN2MAPT
SCHEMBL10740280 0.78 ALDH1A1 (0.54) KMT2AALDH1A1TNFNOD1HTT
SCHEMBL4829407 0.77 MAPT (0.54) KMT2AALDH1A1TNFNOD1HTT
SCHEMBL4831177 0.77 TNF (0.64) KMT2AALDH1A1TNFNOD1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7442704-B2 Amide derivatives ASTRAZENECA AB (SE) 2008-10-28 US disclosed
US-7332483-B2 3-(5-benzamido-2-chlorophenyl)-7-methoxy-3,4-dihydroquinazolin-4-one;cytokines (tumor necrosis factor and interleukins) inhibitor; antiinflammatory agent, rheumatoid arthritis, osteoarthritis, psoriasis, chronic obstructive pulmonary disease ASTRAZENECA AB (SE) 2008-02-19 US disclosed
US-20060281734-A1 Amide derivatives BROWN DEARG S 2006-12-14 US disclosed
US-7008945-B1 Amide derivatives ASTRAZENECA AB (SE) 2006-03-07 US disclosed
US-20050245551-A1 Amide derivatives ASTRAZENECA AB 2005-11-03 US disclosed
CN-1178932-C Amide derivatives 2004-12-08 CN disclosed
EP-1163237-B1 AMIDE DERIVATIVES ASTRAZENECA AB (SE) 2004-05-06 EP disclosed
CN-1350530-A Amide derivatives ASTRAZENECA AB (SE) 2002-05-22 CN disclosed
EP-1163237-A1 AMIDE DERIVATIVES AstraZeneca AB (SE) 2001-12-19 EP disclosed
WO-2000055153-A1 AMIDE DERIVATIVES ASTRAZENECA AB (SE) 2000-09-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245551-A1 Amide derivatives IL6, IL6ST, IL1B KMT2A 2740/4885ALDH1A1 269/4885TNF 31/4885
US-20060281734-A1 Amide derivatives IL6, IL6ST, IL1B KMT2A 2740/4885ALDH1A1 269/4885TNF 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.